Modafinil sits in a curious middle ground between a classic stimulant and a “wakefulness-promoting” drug. It is prescribed for disorders of excessive sleepiness (notably narcolepsy), but it is also widely discussed—sometimes glamorised—as a nootropic. The key scientific question is straightforward: does modafinil reliably enhance cognition, and if so, through what neurological mechanisms and at what cost?

1. Mechanism of action

For years, modafinil was described as acting through diffuse arousal systems (orexin/hypocretin, histamine, and related pathways). Human neuroimaging has made the dopamine story harder to dismiss, and in particular the Dopamine Active Transport (DAT).

DAT actively clears dopamine out of the synapse (the space between neurons) by reuptaking dopamine back into the presynaptic neuron, using the sodium/chloride ion gradient to drive the process. This terminates dopamine signalling, helps recycle dopamine for reuse, and tightly controls dopamine levels. Blocking DAT therefore amplifies dopamine signalling.

1.1 Dopamine active transporter

In a controlled PET (positron emission tomography) study in 10 healthy men were given an oral dose of modafinil (200 mg or 400 mg). A PET brain scan is an imaging test where a small amount of radioactive tracer is injected, and the scanner detects where it’s taken up in the brain. It shows brain function/metabolism rather than just structure—most commonly glucose use (activity) or specific proteins/receptors (depending on the tracer).

The researchers measured a reduced binding of the DAT radioligand by 53.8% (SD 13.8%) in caudate, 47.2% (SD 11.4%) in putamen, and 39.3% (SD 10%) in nucleus accumbens—a pattern interpreted as substantial DAT occupancy (P ≤ .001 across regions) (Volkow et al. 2009).

In the same participants, Craclopride tracer binding fell by 6.1% in caudate, 6.7% in putamen, and 19.4% in nucleus accumbens, consistent with increases in extracellular dopamine (Volkow et al. 2009).

Importantly, the paper notes modafinil’s DAT affinity is much lower than methylphenidate (6.390 μM vs 0.025 μM, respectively), yet clinical doses are far higher—helping explain why a “low-affinity” drug can still produce meaningful DAT engagement in vivo (Volkow et al. 2009).

One PET study found that a 200mg dose of modafinil produced a mean striatal DAT occupancy of 51%. (Kim et al., 2014) This is very similar to a 20mg oral dose of methylphenidate, which produced a 54% DAT blockade 2 hours after dosing. (Volkow et al. 1998). One relevant distinction being that modafinil has a far greater oral bioavailability compared to methylphenidate.

A later PET study in cocaine-dependent patients reported a 65.6% decrease in DAT radioligand binding potential after 2 weeks of modafinil treatment (Karila et al. 2016). While that trial did not support modafinil as an effective anti-cocaine medication, it reinforces the point that sustained clinical dosing can drive large DAT-related imaging changes (Karila et al. 2016).

DAT blockade is a plausible “entry point” for cognitive enhancement and ADHD treatment, because dopamine in prefrontal–striatal circuits helps regulate working memory, cognitive control, and effort allocation.

But dopamine alone rarely predicts whether performance improves: too little can impair signal fidelity; too much can increase distractibility or impulsivity. Modafinil’s comparatively lower euphoric profile than amphetamine-like stimulants is often interpreted as reflecting how dopamine is modulated—more subtly, and in a context shaped by other arousal systems (Volkow et al. 2009).

1.2 Hypothalamic Arousal

Modafinil also engages hypothalamic systems that act as “master regulators” of wakefulness. In a landmark c-Fos mapping study, modafinil administration was associated with activation of hypothalamic arousal regions, supporting the idea that orexin neurons and histaminergic neurons in the tuberomammillary nucleus (TMN) participate in the wake effect (Scammell et al. 2000).

More directly, in mice, modafinil increased histamine release in wild-type animals, but did not increase histamine release in orexin neuron-deficient mice; the authors concluded that intact orexin neurons are required for the histaminergic activation (Ishizuka et al. 2010). In that study, modafinil at 150 mg/kg produced a significant histamine increase in wild-type mice, absent in orexin-deficient animals (Ishizuka et al. 2010).

This orexin→histamine dependency matters for cognition because histamine and orexin systems influence cortical activation, attention stability, and resistance to sleep pressure—features that can indirectly raise performance on demanding tasks by preventing lapses.

1.3 Glutamate & GABA

Beyond catecholamines and hypothalamus, modafinil shifts the brain’s excitatory–inhibitory tone in ways consistent with heightened information throughput.

In rats, microdialysis work found that systemic modafinil (30–300 mg/kg) increased glutamate and decreased GABA in the medial preoptic area and posterior hypothalamus—regions involved in sleep–wake regulation (Ferraro et al. 1999).

Pharmacological manipulation in the same experiments supported an interaction between GABAergic tone and modafinil-linked glutamate increases (Ferraro et al. 1999).

1.4 Intracellular signalling cascades

If DAT/orexin/histamine/glutamate are “surface level levers,” intracellular signalling pathways are where those levers converge into plasticity and gene regulation. In particular, one experimentally tractable pathway is MAPK/ERK.

In rats, intrahypothalamic microinjection of modafinil (10 or 20 μg/1 μL) promoted MAP-kinase phosphorylation in hypothalamus and pons, consistent with activation of intracellular signalling linked to arousal circuitry (Poot-Ake et al. 2015).

A recent mechanistic review also notes elevated MAPK phosphorylation among reported downstream effects, placing ERK/MAPK in the broader cascade of modafinil neurobiology (Hersey et al. 2023).

MAPK/ERK pathways are widely implicated in synaptic plasticity and memory consolidation, so their recruitment offers a plausible bridge between “acute alertness” and longer-timescale cognitive effects—though translating rodent phosphorylation readouts to human enhancement remains nontrivial.

1.5 Epigenetics and gene regulation

The most detailed evidence for “modafinil as a transcriptional modulator” comes from animal work examining epigenetic markers in cognition-relevant cortex. Epigenetics processes involve changing the structures that “package” DNA to make certain genes switch on or off – without changing the underlying genetic code itself.

Histone acetylation is one such epigenetic process. It depends upon adding acetyl groups to histone tails, which generally opens up the structure which packages DNA, making genes easier to turn on. HDAC enzymes (histone deacetylases) remove these acetyl groups, typically tightening this structure and reducing gene expression.

In mice euthanized 1 hour after a single modafinil dose (90 mg/kg i.p.), researchers observed:

• Increased acetylated histone H3 (H3ac) and decreased acetylated histone H4 (H4ac). This should open up genetic structure, making genes more accessible.
• Increased protein levels of HDAC1 and HDAC2. This appears to be a longer term compensatory effect, to try and counteract the rapid histone acetylation.
• Increased expression of the NMDA receptor subunit GluN1
  in medial prefrontal cortex (González et al. 2018).

Crucially, pretreatment with dopamine receptor antagonists modified these effects: a D1-family antagonist (SCH23390, 0.05 mg/kg) or a D2-family antagonist (raclopride, 8 mg/kg) could prevent specific epigenetic/protein changes, implicating dopamine receptor signaling upstream of at least part of the epigenetic response (González et al. 2018).

The same study reported promoter-specific histone acetylation changes at genes relevant to dopamine, adrenergic, orexin, histamine, and glutamatergic receptors, suggesting that even acute modafinil can “prime” transcriptional programs (González et al. 2018).

From a cognitive-enhancement lens, the provocative implication is that modafinil may influence prefrontal cortex function not only by transient neurotransmitter changes, but also by altering chromatin accessibility and receptor-related gene regulation—processes that can shape plasticity and learning capacity.

2. Modafinil reshapes functional connectivity

If dopamine transporters are part of the “hardware,” functional brain networks are the “software layer” where cognition emerges. Several recent fMRI studies have focused less on single regions and more on how modafinil changes communication between networks involved in attention, executive control, salience detection, and internal mentation (default mode network):

• In a thalamus-focused study, a single 100 mg dose of modafinil (25 participants vs 25 placebo) altered connectivity of specific thalamic nuclei—especially pulvinar subdivisions—shifting coupling with attention/salience networks and with default-mode/frontoparietal control systems (Stefano Delli Pizzi et al. 2025).
• In a cerebellar-focused study with the same 100 mg, n=25 modafinil and n=25 placebo, modafinil modulated cerebellar–neocortical connectivity patterns (notably involving crus I and the vermis), with spatial overlap reported between connectivity changes and maps of receptor/transporter expression (Delli Pizzi et al. 2025).

The thalamus and cerebellum are not incidental here: both are increasingly recognised as coordination hubs for attention, timing, and adaptive control—functions often reported as “sharper” under modafinil.

These network studies don’t prove cognitive enhancement by themselves, but they provide plausible circuitry-level routes by which a wake-promoting pharmacology could translate into altered information processing.

3. Evidence for Cognitive performance

The most reliable way to summarise cognitive effects across diverse tasks and populations is meta-analysis. Two syntheses are especially useful because they quantify how big the average effect is, not just whether it exists.

3.1 Healthy & non-sleep-deprived people

A systematic review and meta-analysis across cognitive domains found that modafinil’s overall advantage over placebo was small but statistically significant, with Hedges’ g = 0.10 (95% CI 0.05 to 0.15, P < 0.001) (M. A. Kredlow et al. 2019).

Notably, the authors reported no significant moderation by cognitive domain and no significant difference between 100 mg and 200 mg, and no clear difference between psychiatric vs nonpsychiatric samples in their moderation analyses (Kredlow et al. 2019).

A separate 2020 series of meta-analyses focusing on healthy, non-sleep-deprived adults reported a similarly modest overall effect: SMD = 0.12 for modafinil vs placebo, based on 14 published studies contributing 64 effect sizes, with combined samples including 260 participants from repeated-measures designs and 312 from between-groups designs (135 modafinil, 177 placebo) (C. Roberts et al. 2020).

Importantly, when broken down by domain in that analysis, some components look close to “no effect”: Inhibitory control (SMD 0.09), Selective attention: (SMD −0.01) & Sustained attention (SMD −0.13). (Roberts et al. 2020).

3.2 High Cognitive Control Tasks

One way to reconcile these modest cognitive effects with enthusiastic anecdotes is that modafinil may preferentially help under high cognitive control demands—the tasks where attention must be sustained, distractions suppressed, or rules flexibly applied.

A preregistered randomized, double-blind, placebo-controlled pharmaco-fMRI study in 72 healthy men (modafinil 200 mg, n=35; placebo, n=37) provides a crisp example (J. Li et al. 2020). The investigators separated cognitive conflict (non-emotional interference) from emotional conflict. Modafinil selectively enhanced performance for cognitive conflict, with an effect size reported as d = 0.417 in a robustness analysis (Li et al. 2020).

They also tested metacognition: modafinil improved discrimination sensitivity (t₇₀ = 2.23, p < 0.05, d = 0.527) while leaving confidence indices unchanged—suggesting a pattern where objective performance can improve without inflating self-rated certainty (Li et al. 2020).

This kind of result aligns with a broader theme in the literature: modafinil effects tend to be more detectable when tasks are demanding enough to expose lapses in control, rather than when tests mainly measure simple speed or easy vigilance.

In operational contexts—medicine, transportation, military scenarios—modafinil is often discussed as a countermeasure for sleep loss. Here, the cognitive target is not so much “above baseline brilliance” as damage control: preventing vigilance and reaction time from collapsing.

A 2025 study of sleep deprivation found that modafinil significantly improved psychomotor vigilance and subjective sleepiness at critical overnight time points (2 a.m. and 4 a.m.), with reported significance thresholds of p ≤ 0.034 for vigilance and p ≤ 0.029 for sleepiness (J. Van Cutsem et al. 2025). The authors report condition-by-time effects on sleepiness and describe patterns consistent with later “rebound” sleepiness at some post-deprivation time points.

3.3 EEG Evidence

Beyond fMRI connectivity, EEG/ERP work offers a complementary angle: timing. The P300 component is often interpreted as indexing aspects of stimulus evaluation and attention allocation.

In a small clinical sample of 18 patients with idiopathic hypersomnia taking 200 mg/day, auditory P300 latencies decreased significantly after one week of treatment, with reported p values 0.039 (Fz), 0.002 (Cz), and 0.004 (Pz); P300 amplitude increased at Fz (p = 0.014) but not clearly at Cz or Pz (Mehmet Yaman et al. 2015).

This kind of electrophysiological shift is consistent with “faster” or more efficient processing, but it’s also a reminder that clinical sleepiness populations can respond differently than healthy users, and small samples limit certainty about generalisation.

4. Modafinil: Relative Harm

Modafinil, methylphenidate, and amphetamine all improve alertness and can sharpen certain aspects of performance—but they do so through partly overlapping and partly distinct biology.

Those mechanistic differences matter when you ask a more “long-horizon” question: do these drugs drive the kinds of neurogenesis changes and durable epigenetic “reprogramming” that are often discussed in the context of conventional stimulants and addiction-like adaptations?

4.1 Neurogenesis vs. Neuroplasticity

In rodent work, modafinil has been linked to hippocampal plasticity and to increases in markers of adult neurogenesis under some conditions—especially when baseline neurogenesis is impaired or under short exposures.

• Direct neurogenesis readouts (adult dentate gyrus): In mice given modafinil (64 mg/kg i.p.) once daily, 4 days of treatment increased proliferation in the dentate gyrus (BrdU labeling) and resulted in more newborn granule cells 3 weeks later; extending treatment to 14 days increased newborn Prox1(+) granule cells but did not add further proliferation/survival gains beyond the short regimen (Brandt et al. 2014).
• Rescuing neurogenesis when it is falling: In an ovariectomy model (a state associated with reduced hippocampal plasticity), chronic modafinil was reported to prevent declines in LTP maintenance and neurogenesis alongside behavioral benefits (Yan et al. 2021).

For methylphenidate and amphetamine, the neurogenesis picture is more dose-, age-, and exposure-pattern dependent—and more entangled with reward-circuit adaptations.

• Methylphenidate shows a “dose–response split”: In mice treated for 28–56 days, low-dose methylphenidate increased hippocampal trophic/proliferation-linked proteins (VEGF, TrkB, β-catenin) and was interpreted as supporting proliferation/survival, whereas high-dose methylphenidate was associated with later reductions in β-catenin and, by 56 days, decreases in VEGF/TrkB/β-catenin consistent with poorer survival of newly generated neurons (Oakes et al. 2019).
• Amphetamine can increase survival of new neurons under “therapeutic-like” schedules, while high-dose exposure carries known neurotoxicity risks: Chronic d-amphetamine from adolescence into adulthood increased survival/differentiation of BrdU-labeled cells into neurons without changing Ki67 proliferation, but the same paper emphasizes that high doses in the broader literature can damage dopamine terminals and induce cell death (Dabe et al. 2012).
• Methamphetamine and compulsive-like exposure patterns are strongly associated with impaired hippocampal plasticity across studies/reviews, including reductions in neurogenesis and LTP and increased apoptosis—often discussed as “maladaptive plasticity” relevant to addiction phenotypes (e.g., Galinato et al. 2014 review paper).

Taken together, the direction of modafinil’s neurogenesis findings in animals tends to align with supporting hippocampal plasticity (or rescuing it when impaired), whereas conventional stimulants span from potentially pro-neurogenic effects under limited/therapeutic-like dosing to clear maladaptive plasticity in abuse-like patterns (especially methamphetamine).

4.2 Epigenetic changes

A particularly informative set of studies compares modafinil directly to methamphetamine in mice, focusing on the medial prefrontal cortex (mPFC), cognition, and epigenetic markers.

After repeated dosing, methamphetamine produced object recognition memory impairment (novel object recognition; ANOVA-Bonferroni F = 4.59, p = 0.024), whereas modafinil-treated mice behaved like controls (González et al. 2017).

Repeated methamphetamine decreased total H3ac (F = 8.27, p = 0.003) and H4ac (F = 13.48, p = 0.0003) and increased global DNA 5-methylcytosine (F = 4.43, p = 0.028) in mPFC; modafinil did not share this global “hypoacetylation + hypermethylation” pattern (González et al. 2017).

In repeated-treatment ChIP assays, methamphetamine showed reduced H3ac enrichment at multiple receptor promoters (e.g., Drd2 p = 0.001, Hcrtr1 p = 0.016, Hcrtr2 p = 0.018, Grin1 p = 0.044), while modafinil uniquely increased H3ac at the Adra1b promoter (p = 0.045) and increased Adra1b mRNA (F = 5.55, p = 0.018) (González et al. 2017).

A follow-up mapping of histone acetylation at HDAC/sirtuin promoters found many methamphetamine-specific changes (e.g., decreased H3ac enrichment at Hdac1 p = 0.009, Hdac2 p = 0.025, Hdac8 p = 0.005), with class III/IV HDAC-related loci notably responsive to repeated methamphetamine and far less so to modafinil; the authors explicitly frame these differences as candidates for “cognitive-enhancing vs cognitive-impairing” divergence (González et al. 2019).

4.3 Transcriptional changes

In an acute comparison study, single-dose modafinil and methamphetamine both shifted global histone acetylation in mPFC (↑H3ac, ↓H4ac) and increased HDAC1/HDAC2 and NMDA subunit GluN1 protein; dopamine receptor antagonists (D1 and D2) blocked specific components of these effects (González et al. 2019).

But crucially, the same paper reports that only methamphetamine produced a broad set of mRNA changes aligned with the acetylation changes (e.g., increased Drd1a and others, decreased Grin1), consistent with tighter coupling to transcriptional remodeling than modafinil under these conditions.

4.4 Chronic Stimulant Lasting Adaptation

Methylphenidate produces reward-circuit structural/transcription-factor changes associated with durable adaptation. In nucleus accumbens medium spiny neurons, chronic methylphenidate (15 mg/kg for 14 days) increased dendritic spine density in specific cell types:

• Class 2 spines in D1-MSN were 115% of saline in NAcc shell and 124% in core.
• In D2-MSN shell, class 2 spines reached 143% of saline.
• It also increased ΔFosB expression in D1-MSN, in some regions more than cocaine in the same experiment (Kim et al. 2009).

Amphetamine has an established epigenetic “switching” narrative (acute activation becoming chronic repression), including altered histone acetylation at immediate early gene promoters (e.g., c-fos) and chronic-associated increases in DNA methylation machinery (Dnmt1) and MeCP2 phosphorylation through D1-like receptor pathways (McCowan et al. 2015).

Persistent (post-withdrawal) methylation/gene-expression differences have been reported after amphetamine exposure. After 14 days of amphetamine followed by a 14-day withdrawal, one study found decreased global DNA methylation across reward-related regions and 25 genes with altered expression attributable to amphetamine (vs 16 for nicotine), emphasizing that persistent epigenetic states can differ from immediate post-drug signatures (Mychasiuk et al. 2013).

In humans, stimulant treatment can correlate with measurable methylation associations, though causal interpretation is difficult. For example, an 8-week open-label methylphenidate trial in 74 youth examined methylation across 28 CpG sites of DRD4 and reported a significant interaction involving CpG7 and prenatal maternal stress predicting changes in omission errors (p = 0.0001) (Kim et al. 2018).

4.5 Modafinil lasting adaptation

Modafinil can engage dopamine-dependent signaling and measurable chromatin regulation, but direct head-to-head animal data in mPFC suggest it does not reproduce the more global epigenetic pattern seen with methamphetamine—specifically methamphetamine’s combined reductions in histone acetylation and increases in DNA methylation alongside cognitive impairment (González et al. 2017).

Modafinil’s longer-term animal findings include hippocampal plasticity/neurogenesis support in some paradigms (Brandt et al. 2014; Yan et al. 2021). In contrast, methylphenidate and amphetamine have more extensive evidence for reward-circuit remodelling associated with durable transcriptional programs (ΔFosB, spine changes) and for addiction-relevant epigenetic machinery changes—especially under high-dose, repeated, or abuse-like patterns (Kim et al. 2009; McCowan et al. 2015; Mychasiuk et al. 2013).

4.6 Different mechanism, different effects

Modafinil’s comparatively “milder” neurological harm profile—relative to conventional stimulants like amphetamine and methylphenidate. A central split among stimulants is between:

• Transporter blockers (e.g., methylphenidate): raise synaptic dopamine mainly by inhibiting reuptake at DAT (and often NET).
• Transporter releasers (e.g., amphetamine, methamphetamine): raise dopamine not only by affecting uptake, but by actively driving dopamine outward through DAT (reverse transport/efflux) and by perturbing vesicular storage via VMAT2.

This distinction matters because the “releaser” mechanism tends to increase cytosolic dopamine inside terminals—fuel for oxidative stress chemistry—while also producing stronger reinforcement-related dopamine dynamics.

Mechanistically, amphetamine-induced dopamine efflux has been shown to depend on concerted actions at DAT and VMAT2 (Støier et al. 2023). In classic electrophysiology work, amphetamine also produced DAT-mediated efflux via exchange-like mechanisms and a rapid “channel-like” mode (Kahlig et al. 2005). Modafinil, in contrast, is better characterized—especially at clinically relevant doses—as a DAT blocker (not a robust dopamine releaser).

A blocker-style increase in synaptic dopamine is often more “contained” to synaptic signalling. A releaser-style mechanism tends to more directly elevate cytosolic dopamine and disrupt vesicular handling—conditions more tightly linked in the literature to neurotoxic cascades (oxidative stress, mitochondrial strain) when exposures are high or repeated.

Reviews discussing stimulant neurotoxicity and neuroprotection repeatedly emphasize that neurotoxic risk is linked to abnormal cytosolic dopamine accumulation and reactive oxygen species formation. One review notes methylphenidate’s potential to be neuroprotective against methamphetamine toxicity, framed around preventing abnormal cytosolic dopamine buildup and downstream ROS chemistry (Volz & Schenk 2008).

Amphetamine-class releasers, by acting at VMAT2 (vesicular storage) and DAT (efflux), more directly create the intracellular conditions associated with these damaging cascades (Kahlig et al. 2005; Støier et al. 2023). Modafinil, as primarily a DAT blocker in vivo, is less likely to reproduce the same degree of vesicular disruption and cytosolic overflow under typical dosing—one mechanistic reason its long-term harm signal looks weaker.

References

Volkow, N. D., Fowler, J. S., Logan, J., et al. (2009). Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. “https://pmc.ncbi.nlm.nih.gov/articles/PMC2696807/
“

Karila, L., et al. (2016). Dopamine Transporter Correlates and Occupancy by Modafinil in Cocaine-Dependent Patients: A Controlled Study With High-Resolution PET and [(11)C]-PE2I. “https://www.nature.com/articles/npp201628
“

Scammell, T. E., et al. (2000). Hypothalamic Arousal Regions Are Activated during Modafinil-Induced Wakefulness. “https://pmc.ncbi.nlm.nih.gov/articles/PMC6773149/
“

Ishizuka, T., Murotani, T., Yamatodani, A. (2010). Modafinil activates the histaminergic system through the orexinergic neurons. “https://pubmed.ncbi.nlm.nih.gov/20696213/
“

Ferraro, L., et al. (1999). The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. “https://pubmed.ncbi.nlm.nih.gov/10088135/
“

Poot-Aké, A., et al. (2015). Intrahypothalamic administration of modafinil increases expression of MAP-kinase in hypothalamus and pons in rats. “https://pubmed.ncbi.nlm.nih.gov/25921741/
“

González, B., et al. (2019) (online/PMC issue metadata lists 2018 in some records). The effects of single-dose injections of modafinil and methamphetamine on histone acetylation… and GluN1 in mouse medial prefrontal cortex. “https://pmc.ncbi.nlm.nih.gov/articles/PMC8424782/
“

U.S. Food and Drug Administration (2010). PROVIGIL® (modafinil) Tablets [C-IV] Prescribing Information (label). “https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020717s030s034s036lbl.pdf
“

Robertson, P. Jr., et al. (2002). Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. “https://pubmed.ncbi.nlm.nih.gov/11823757/
“

Wisor, J. P. (2013). Modafinil as a catecholaminergic agent. “https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2013.00139/full
“

Hersey, M., et al. (2023). Modafinil, an atypical CNS stimulant? “https://pmc.ncbi.nlm.nih.gov/articles/PMC12004278/
“

Moritz D. Brandt et al. (2014). Short- and long-term treatment with modafinil differentially affects adult hippocampal neurogenesis. “https://pubmed.ncbi.nlm.nih.gov/25158676/
“

Y. D. Yan et al. (2021). Chronic modafinil therapy ameliorates depressive-like behavior… (includes hippocampal plasticity/neurogenesis measures in an ovariectomy model). “https://pmc.ncbi.nlm.nih.gov/articles/PMC7870893/
“

H. V. Oakes et al. (2019). Neurogenesis within the hippocampus after chronic methylphenidate exposure. “https://pubmed.ncbi.nlm.nih.gov/30370451/
“

E. C. Dabe et al. (2013). Chronic d-amphetamine administered from childhood to adulthood dose-dependently increases the survival of new neurons in the hippocampus… “https://pubmed.ncbi.nlm.nih.gov/23178911/
“

Betina González et al. (2017). Repeated methamphetamine and modafinil induce differential cognitive effects and specific histone acetylation and DNA methylation profiles in the mouse medial prefrontal cortex. “https://pmc.ncbi.nlm.nih.gov/articles/PMC6983674/
“

Betina González et al. (2019/2020). HDAC superfamily promoters acetylation is differentially regulated by modafinil and methamphetamine in the mouse medial prefrontal cortex. “https://pmc.ncbi.nlm.nih.gov/articles/PMC8388191/
“

Betina González et al. (2019). The effects of single-dose injections of modafinil and methamphetamine on epigenetic and functional markers in the mouse medial prefrontal cortex: potential role of dopamine receptors. “https://pubmed.ncbi.nlm.nih.gov/30056065/
“

Y. Kim et al. (2009). Methylphenidate-induced dendritic spine formation and ΔFosB expression in nucleus accumbens. “https://pubmed.ncbi.nlm.nih.gov/19202072/
“

Eric J. Nestler (2001). ΔFosB: a sustained molecular switch for addiction. “https://pubmed.ncbi.nlm.nih.gov/11572966/
“

T. J. McCowan et al. (2015). The Epigenetic Mechanisms of Amphetamine. “https://pmc.ncbi.nlm.nih.gov/articles/PMC4955852/
“

R. Mychasiuk et al. (2013). Persistent gene expression changes in NAc, mPFC, and OFC associated with previous nicotine or amphetamine exposure. “https://pubmed.ncbi.nlm.nih.gov/24021241/
“

Johanna Inhyang Kim et al. (2018). Effects of Interaction Between DRD4 Methylation and Prenatal Maternal Stress on Methylphenidate-Induced Changes in Continuous Performance Test Performance in Youth with ADHD. “https://pubmed.ncbi.nlm.nih.gov/29905488/
“

H. Steiner (2012). Addiction-Related Gene Regulation: Risks of Exposure to Cognitive Enhancers vs Other Psychostimulants. “https://pmc.ncbi.nlm.nih.gov/articles/PMC3525776/
“

C. Xu et al. (2015). Effects of addictive drugs on adult neural stem/progenitor cells. “https://pmc.ncbi.nlm.nih.gov/articles/PMC4833708/
“

Chitra D. Mandyam et al. (2008). Varied access to intravenous methamphetamine self-administration differentially alters adult hippocampal neurogenesis. “https://pmc.ncbi.nlm.nih.gov/articles/PMC2587157/
“

Melissa H. Galinato et al. (2015). Methamphetamine differentially affects BDNF and cell death… (discusses METH-linked maladaptive hippocampal plasticity including neurogenesis/LTP). “https://pubmed.ncbi.nlm.nih.gov/25463524/
“

Juan J. Canales (2010). Role for neurogenesis in the adult hippocampus (review on stimulant abuse, cognition, and adult hippocampal neurogenesis). “https://pubmed.ncbi.nlm.nih.gov/20700045/

WooChan Kim, Amane Tateno, Ryosuke Arakawa, Takeshi Sakayori, Yumiko Ikeda, Hidenori Suzuki, Yoshiro Okubo, In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [¹⁸F]FE-PE2I, International Journal of Neuropsychopharmacology, Volume 17, Issue 5, May 2014, Pages 697–703, https://doi.org/10.1017/S1461145713001612

Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 1998 Oct;155(10):1325-31. doi: 10.1176/ajp.155.10.1325. PMID: 9766762.